Private Versus Public Sector Insurance Coverage for Drug Abuse
ResearchPublished 1993
ResearchPublished 1993
This study examined financing mechanisms currently in place for treating drug abuse, focusing primarily on differences between private and public insurance mechanisms. Within the private sector, insurance coverage for drug abuse treatment is quite restrictive. Limitations typically exist on the type and amount of treatment that can be received per year or per lifetime, and benefits may quickly be exhausted. Limitations also exist with regard to public insurance funding. Eligibility requirements and the authorized settings in which care may be provided are extremely restrictive. It has been argued that public funding for drug abuse should be mainstreamed into Medicaid. However, this is not likely to occur due to significant institutional barriers, and in particular to the highly restrictive eligibility requirements for public programs.
This publication is part of the RAND monograph report series. The monograph report was a product of RAND from 1993 to 2003. RAND monograph reports presented major research findings that addressed the challenges facing the public and private sectors. They included executive summaries, technical documentation, and synthesis pieces.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.